Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
H Miles
HM
Prince
Dirk
D
Hönemann
Andrew
A
Spencer
David A
DA
Rizzieri
Edward A
EA
Stadtmauer
Andrew W
AW
Roberts
Nizar
N
Bahlis
Guido
G
Tricot
Bill
B
Bell
Douglas J
DJ
Demarini
A
A
Benjamin Suttle
Katherine L
KL
Baker
Lini N
LN
Pandite
D000328:Adult; D000368:Aged; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007191:Indazoles; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012449:Safety; D016879:Salvage Therapy; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C516667:pazopanib